Sovleplenib is under clinical development by Hutchison MediPharma and currently in Phase I for Marginal Zone B-cell Lymphoma. According to GlobalData, Phase I drugs for Marginal Zone B-cell Lymphoma have an 82% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how Sovleplenib’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Sovleplenib overview
Sovleplenib (HMPL-523) is under development for the treatment of hematological cancers such as relapsed and refractory Hodgkin lymphoma, chronic lymphocytic leukemia (CLL), follicular lymphoma, coronavirus disease 2019 (COVID-19), waldenstrom macroglobulinemia, mantle cell lymphoma, multiple myeloma, diffuse large B-cell lymphoma and immunological diseases including autoimmune disorder, primary immune thrombocytopenia, Hodgkin and non-Hodgkin lymphoma, marginal zone B-cell lymphoma and autoimmune hemolytic anemia. It is administered orally as a tablet and suspension. The drug candidate targets spleen tyrosine kinase (Syk). It was also under development for acute myeloid leukemia, multiple sclerosis, lupus erythematosus and rheumatoid arthritis. The drug candidate is a new molecular entity (NME).
See Also:
Hutchison MediPharma overview
Hutchison MediPharma (HMPL) carries out discovery, development and commercialization of therapeutics in oncology and autoimmune diseases. The company’s products include savolitinib, fruquintinib, sulfatinib, HMPL-523, epitinib, theliatinib, HMPL-453, HMPL-689 and HMPL-004. It develops drug discovery technologies in molecular and cell biology, high throughput screening, genomics and informatics to support research and development projects. HMPL’s research and development programs comprise gene-targeted and cell-based screening assays, ligand-dependent screening assays and signal transduction pathway screening assays. The company’s products serve in the fields of medicinal chemistry, pharmacology, oncology, cardiovascular and respiratory diseases, and antiviral treatments. It operates through its two offices in Pudong, China. HMPL is headquartered in Pudong, China.
For a complete picture of Sovleplenib’s drug-specific PTSR and LoA scores, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
